Rising usage of atypical antipsychotics, omega?3 fatty acids, antidepressants, glutamateric neurotransmission modulators, erythropoietin, COX?2 inhibitors and N?acetylcysteine have anti?apoptotic properties which can help in brain maturational processes from psychotic disorders. Clinical trial processes suggested that these category of drugs help in preventing the onset of frank psychosis. A company named, Astrocyte Pharmaceuticals Inc., which is a drug development company is engaged in providing advanced breakthroughs in neuroprotection drugs market to repair neurons that are caused due to brain injury. The company is currently undergoing through several programs to provide potential treatment for TBI, concussion and acute ischemic stroke amongst others. The company’s novel product AST-004 aims to begin human Phase I clinical safety trials in 2020 and human Phase II trials in 2021. Another company named Bionure Farma, S.L is focusing towards areas such as acute optic neuritis and multiple sclerosis for which there are highly unmet medical needs. The company’s class compound named BN201 demonstrated remyelination, axonal protection and neuronal survival promotion in preclinical models. This is estimated to make it an ideal product for nervous system diseases which are ischemic, inflammatory and toxic in nature. It has been reported that there is an impregnable need for neuroprotectants and as of now there are no remyelinating drug that has got approval. As only a few products are in clinical development, this can be a great passage for the company Bionure to be one of the major participants in the global neuroprotection drugs market. Also, these approvals are not passed by regulatory organizations at once. Such a factor sometimes critically affect the neuroprotection drugs market demand. The company needs strong evidence that the concerned drug is both safe and effective in nature. This can be achieved through in-vivo and in-vitro analysis. But this also depends on the diseases and treatments in question. However, recent biotechnology advancements have the ability at predicting the effects of drugs on the human body, which can eventually replace the animal testing phase and this in turn can help in achieving new disease treatments faster and also can reach the patients quickly. These unique factors are expected to propel the global neuroprotection drugs market from 2019 to 2027.
Global Neuroprotection Drugs Market Share in 2018, By Region
Key findings of the report:
Global Neuroprotection Drugs Market: